Research programme: LRRK2 inhibitors - Denali/Genentech

Drug Profile

Research programme: LRRK2 inhibitors - Denali/Genentech

Latest Information Update: 30 Aug 2016

Price : $50

At a glance

  • Originator Genentech
  • Developer Denali Therapeutics Inc
  • Class Antiparkinsonians; Small molecules
  • Mechanism of Action LRRK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Parkinson's disease

Most Recent Events

  • 25 Aug 2016 Early research in Parkinson's disease in USA (unspecified route)
  • 25 Aug 2016 Denali Therapeutics in-licenses LRRK2 inhibitors programme from Genentech
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top